Corneal Crosslinking for Keratoconus

Keratoconus affects an estimated 1 in 2,000 people worldwide, and for decades the only real answers were hard contact lenses or, eventually, a corneal transplant. That changed in 2016 when the FDA approved the first corneal crosslinking treatment in the United States — a procedural milestone that gave ophthalmologists a way to stop the disease in its tracks rather than simply manage its symptoms. The procedure does not restore lost vision, but it does something arguably more important: it halts the progressive structural collapse that drives vision loss in the first place.

What Keratoconus Does to the Cornea

The cornea's dome shape is maintained by a tight lattice of collagen fibrils. In keratoconus, that lattice weakens — the bonds between fibrils degrade, the structural integrity fails, and the cornea begins to thin and bulge forward into an irregular cone. The resulting distortion scatters light before it ever reaches the retina, producing blurring, halos, and the characteristic ghost images that keratoconus patients describe (National Eye Institute).

The disease typically appears in adolescence or early adulthood and progresses at an unpredictable rate. Some patients stabilize on their own; others progress rapidly toward legal blindness without intervention. Genetics play a role — first-degree relatives of affected individuals have a meaningfully higher risk — but eye rubbing, atopic disease, and UV exposure are also implicated as contributing factors (MedlinePlus).

How Corneal Crosslinking Works

Corneal crosslinking (CXL) reinforces the weakened collagen lattice using two components in combination: riboflavin (vitamin B2) eye drops and ultraviolet-A (UVA) light. The riboflavin acts as a photosensitizer; when activated by UVA at a wavelength of 365 nanometers, it generates reactive oxygen species that form new covalent bonds between collagen fibrils. The result is a biomechanically stiffer cornea — more resistant to the progressive ectatic deformation that defines keratoconus (NCBI Bookshelf).

The FDA-approved version of the procedure uses PHOTREXA Viscous (riboflavin 0.146% in 20% dextran) and PHOTREXA (riboflavin 0.146% in saline), delivered with the KXL System — a purpose-built UVA light delivery device. The approval was based on randomized controlled trial data demonstrating statistically significant reduction in maximum keratometry values (Kmax) at 12 months compared to sham-treated eyes (FDA).

Epithelium-Off vs. Epithelium-On

The standard FDA-approved protocol is epithelium-off (epi-off) CXL. The corneal epithelium — the outermost cellular layer — is removed mechanically or chemically before riboflavin is applied, allowing adequate drug penetration into the stromal tissue. This approach has the most robust long-term evidence behind it and is considered the reference standard by the American Academy of Ophthalmology.

Epithelium-on (transepithelial or epi-on) CXL, which preserves the surface layer, is used in some clinical settings and has been the subject of active research listed on ClinicalTrials.gov. The appeal is faster recovery and lower infection risk. The tradeoff, at least based on peer-reviewed literature indexed on PubMed, is generally less predictable stromal penetration and efficacy data that remains less definitive than the epi-off approach.

Who Is a Candidate?

Patient selection matters considerably. The AAO Preferred Practice Pattern for Cornea identifies progressive keratoconus — documented worsening of keratometry or corneal topography over time — as the primary indication. CXL is most effective when performed before structural loss is severe; a minimum corneal thickness of 400 microns (at the thinnest point, after epithelial removal) is a standard safety threshold to prevent UVA damage to the endothelium and anterior chamber structures.

Age is a practical consideration too. Younger patients tend to have more aggressive disease progression, which makes early intervention particularly valuable. Adults with stable disease may not benefit as much from the procedure, though the risk calculus shifts when topographic instability is documented.

Contraindications include corneal scarring that significantly reduces best-corrected visual acuity, active ocular infection, and corneas too thin to meet the 400-micron threshold safely.

The Procedure and Recovery

In the epi-off protocol, the central 9 millimeters of corneal epithelium is removed, followed by application of riboflavin drops over approximately 30 minutes to saturate the stroma. The KXL system then delivers 30 minutes of UVA irradiation at 3 mW/cm² for a total energy dose of 5.4 J/cm².

Recovery involves a bandage contact lens for the first few days while the epithelium regenerates. Pain, photophobia, and blurred vision in the first week are expected — not side effects in the alarming sense, but the predictable consequence of removing a surface layer that will regenerate. Most patients return to functional vision within 1 to 2 weeks, though stromal haze and fluctuating refraction can persist for 3 to 6 months post-procedure (according to the American Academy of Ophthalmology).

What Crosslinking Can and Cannot Do

The honest accounting: CXL is a stabilizing procedure, not a restorative one. The goal is to arrest progression and preserve existing vision, not to reverse corneal irregularity or eliminate the need for contact lens correction. A subset of patients do show modest improvement in Kmax values after the procedure — the cornea relaxes slightly as the new collagen bonds settle — but this is a secondary benefit, not the primary mechanism.

Patients who expect to discard their rigid gas-permeable lenses after CXL will likely be disappointed. Those who expect to keep the vision they have and avoid a transplant have realistic expectations — and that is a genuinely meaningful outcome for a condition that, left unchecked, remains one of the leading indications for corneal transplantation in younger adults.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)